OKX Launches X-Perps in Europe: MiFID Regulated Crypto Derivatives with up to 10x Leverage
15.4.2026 12:30:00 CEST | Business Wire | Press Release
OKX, a leading global fintech company and crypto trading platform, today announced the launch of X-Perps, MiFID-regulated five-year expiry crypto derivatives with up to 10× leverage, for retail and institutional traders in Europe.
Available to eligible customers across the European Economic Area (EEA), X-Perps includes market-leading advanced margin capabilities through a unified account, including real-time, multi-asset and multicurrency mode.
X-Perps enables capital-efficient trading of volatility and directional positions within a regulated framework. It uses a funding rate mechanism that keeps derivatives pricing aligned with the underlying spot market, creating funding rate arbitrage opportunities alongside familiar crypto-native mechanics and institutional-grade risk management.
Built on OKX's globally renowned derivatives infrastructure, X-Perps combines deep liquidity, low-latency matching and high-throughput order handling for fast, resilient execution across all market conditions.
With X-Perps, traders can:
- Trade more with less capital — Up to 10× leverage
- Optimize capital with portfolio margin in a unified account — Spot and derivatives positions are netted across a single risk framework, reducing margin requirements on hedged or offsetting exposures.
- Manage risk in real-time — Continuous margining with no settlement delays or batch processing
- Access professional trading tools — Advanced order types, charting, mobile interface and full API support
- Execute with speed and liquidity — Low-latency matching and deep liquidity on OKX’s global infrastructure
- Use multi-asset collateral — EUR, USD, and major crypto assets accepted without conversion
- Trade with clarity and support — Transparent fees, education resources, and responsive customer service
X-Perps delivers a professional-grade trading experience within a regulated European framework, combining advanced tools, strong risk controls, and reliable execution. Launching with pairs for BTC, ETH, ADA, DOGE, PEPE, LTC, PUMP, SOL, XRP, and SUI, OKX will be rolling out more pairs and exploring high-demand products for retail and institutional traders as it builds out its fully featured, regulated European derivatives platform.
"Europe is a global leader in regulated digital asset markets and a key priority for OKX," said Erald Ghoos, CEO of OKX Europe. "Derivatives sit at the core of crypto markets today. With X-Perps, we’re extending our proven, high-performance derivatives offering into a regulated European framework, giving both institutions and retail traders access at scale. Combined with deep liquidity, OKX delivers a level of depth, performance and risk management that few platforms can match. Our goal is simple: to provide Europe’s traders with the most complete and trusted derivatives trading environment in the market."
X-Perps is supported by established OKX risk systems, including negative balance protection and continuous exposure monitoring. It is backed by the company’s global Proof-of-Reserves and asset verification frameworks.
In parallel, OKX is expanding European customer education resources, including multilingual learning content, derivatives risk guides, and provides platform tools that help traders better understand leverage, liquidation thresholds, and margin requirements before opening positions. European traders must pass an appropriateness assessment, demonstrating their knowledge and trading experience before trading X-Perps on OKX.
The X-Perps launch forms part of OKX’s broader European strategy focused on regulated growth, product depth and user protection, delivering advanced trading capabilities through a more transparent and risk-managed approach.
About OKX
OKX is a fintech company on a mission to modernize money and markets. Today it is trusted by more than 120 million people around the world who use OKX services to invest, transact and trade digital assets across a number of financial instruments including spot, futures, and decentralized markets. As one of the world's largest platforms, OKX is known for its exchange, wallet, and onchain ecosystem used by everyday people and large institutions.
OKX maintains regional offices in the United States, Europe, UAE and Singapore with a number of local offices across São Paulo, Hong Kong, the Republic of Türkiye, and Australia. Over the past several years, it has built one of the world's most comprehensive regulatory compliant, licensed fintech companies.
OKX is steadfastly committed to transparency and security and publishes Proof of Reserves reports on a monthly basis to ensure customer funds are always protected and available to people. To learn more about OKX, download our app or visit: okx.com.
Regulatory disclosure
X-Perps are leveraged products; leverage can amplify gains and losses. Losses may occur quickly and these products may not be suitable for all investors. The value of your investment can go down as well as up. If you invest in this product you may lose some or all of the money you invest.
OKX Europe Markets Limited is authorised and regulated by the Malta Financial Services Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260415510125/en/
Contacts
okx@wachsman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom